Key result
Surgical resection plus adjuvant lenvatinib achieves recurrence-free survival at nearly 10 months.
Why the study?
Hepatocellular carcinoma with intracavitary metastasis extending to the heart is an extremely rare late-stage disease with no effective treatment and median survival less than 2 months.
Case Report (n=1)
Aggressive surgical resection and IVC reconstruction followed by targeted therapy can offer favorable outcomes and recurrence-free survival in highly selected patients with right atrial metastasis from hepatocellular carcinoma.
Case of advanced HCC with cardiac metastasis is hypothesis-generating; leaves open whether any intervention can meaningfully extend survival.
RATIONALE: Hepatocellular carcinoma (HCC) with intracavitary metastasis extending to the heart, also known as inferior vena cava (IVC) tumor thrombus, is an extremely rare late-stage disease with no effective treatment. In fact, the median survival is reportedly less than 2 months; thus, there is an urgent need for better treatment. PATIENT CONCERNS: In this study, a 48-year-old patient was admitted to our hospital to seek medical treatment for advanced primary HCC with right atrial metastasis. DIAGNOSIS: The patient was diagnosed as primary HCC with a large mass in the right lobe of the liver and intracavitary metastasis to the right atrium. INTERVENTIONS: A new surgical treatment of right hemihepatectomy, complete resection of the involved IVC and the right atrium thrombus, plus reconstruction of the resected IVC using autologous pericardial tube graft were undertaken and successfully performed. OUTCOMES: The patient recovered rapidly, and 14 days after the surgical procedures, he was discharged from the hospital. Notably, serum levels of alpha-fetoprotein dropped to normal range and no clinical signs of recurrence were observed during follow-up. LESSONS: This report highlights an unusual case of right atrial metastasis from HCC. The surgical treatment appeared to be suitable and effective, together with postoperative administration of lenvatinib, a tyrosine kinase multitarget inhibitor selected by performing whole-exome sequencing. These therapies have offered favorable clinical outcomes such as prevention of recurrence and prolongation of patient survival. In addition, clinicians may benefit from our experience for their future treatment of patients with similar clinical conditions.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) conducted a case report in Hepatocellular carcinoma with right atrial metastasis (n=1). Surgical resection and postoperative lenvatinib was evaluated on Clinical recovery, recurrence-free survival, and serum alpha-fetoprotein (AFP) levels. Surgical resection combined with postoperative lenvatinib resulted in a rapid recovery, normalization of serum alpha-fetoprotein levels, and no clinical signs of recurrence at nearly 10 months of follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: